A new catheter-integrated drug-delivery system for controlled intravesical mitomycin C release

Stærk, Kristian; Hjelmager, Janni Søvsø; Alm, Martin; Thomsen, Peter; Andersen, Thomas Emil

doi:10.1016/j.urolonc.2022.05.022

Cited by 8 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To compare how the ex-vivo porcine LUT model reflects catheterization in live animals, a recently established porcine model that facilitates catheterization in-vivo 19 , 28 was used. Although the ex-vivo tests were performed on male porcine LUTs, the in-vivo studies had to be performed in female pigs.…”

Section: Resultsmentioning

confidence: 99%

Development of an ex-vivo porcine lower urinary tract model to evaluate the performance of urinary catheters

Tentor

Schrøder

Nielsen

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Intermittent catheterization is the gold standard method for bladder management in individuals with urinary retention and/or incontinence. It is therefore important to understand the performance of urinary catheters, especially on parameters associated to risks of developing urinary tract infections, and that may impact the quality of life for urinary catheter users. Examples of such parameters include, urine flowrate, occurrence of flow-stops, and residual urine left in the bladder after flow-stop. Reliable in-vitro and/or ex-vivo laboratory models represent a strong asset to assess the performance of urinary catheters, preceding and guiding in-vivo animal studies and/or human clinical studies. Existing laboratory models are generally simplified, covering only portions of the catheterization process, or poorly reflect clinical procedures. In this work, we developed an ex-vivo porcine lower urinary tract model that better reflects the catheterization procedure in humans and allows to investigate the performance of standard of care catheters. The performance of three standard of care catheters was investigated in the developed model showing significant differences in terms of flowrate. No differences were detected in terms of residual volume in the bladder at first flow-stop also when tuning the abdominal pressure to mimic a sitting down and standing up position. A newly discovered phenomenon named hammering was detected and measured. Lastly, mucosal suction was observed and measured in all standard of care catheters, raising the concern for microtrauma during catheterization and a need for new and improved urinary catheter designs. Results obtained with the ex-vivo model were compared to in-vivo studies, highlighting similar concerns.

show abstract

Section: Resultsmentioning

confidence: 99%

Development of an ex-vivo porcine lower urinary tract model to evaluate the performance of urinary catheters

Tentor

Schrøder

Nielsen

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…However, until now, urine specimens have been collected by either bladder catheterization or sterile bladder aspiration, which are both procedures that require the need for anaesthesia. [9][10][11][12] Although well-established protocols for shortterm anaesthesia exist, they often involve various combinations of opioids, benzodiazepines and alpha-2-agonists, which are associated with adverse effects such as obstipation, nausea, extended recovery, drug interactions or unwanted alterations in the animal's physiology that can interfere with the outcome of the study. [13][14][15] Therefore, the need for anaesthesia is a major limitation as it is not only stressful for the animal and increases procedural costs, but also limits the frequency of which urine specimens can be collected as daily anaesthesia for many days in a row is undesirable due to the concern for the animal's welfare.…”

Section: Introductionmentioning

confidence: 99%

Clean-catching urine from pigs: A method for collecting quality specimens for urinalysis and microbiological culturing in a laboratory environment

2022

Self Cite

View full text Add to dashboard Cite

Urine is an important biological specimen for assessing various metabolic functions and drug clearance. In urinary tract infection research, urine is particularly important as urinary bacterial titres constitute the main diagnostic outcome for assessing the course of infection. Collecting uncontaminated urine samples from pigs can be done by bladder catheterization or suprapubic bladder aspiration, which are both laborious and invasive procedures that require the need for anaesthesia. To improve animal welfare and optimize urine sampling protocols, we developed a method of clean-catching midstream urine specimens from pigs during spontaneous micturition. The quality of urine specimens collected by clean-catch, bladder catheter and suprapubic bladder aspiration were compared using microbiological culturing. We show that urine specimens collected by clean-catch are only minimally contaminated by skin- and vaginal-commensals with no influence on urinary bacterial titres during ongoing infection. In conclusion, we describe a method in which spontaneous micturition can be prompted in pigs, facilitating fast and reliable collection of quality specimens suitable for microbiological culturing. The method supersedes the need for anaesthesia, which not only represents a considerable refinement in terms of animal welfare but also facilitates more frequent collection of specimens that can enhance the scientific outcome of experimental animal studies in pigs.

show abstract

“…In vitro results showed a sustained release of MMC for up to 12 days with an inhibitory effect against HTB-9 (ATCC bladder carcinoma cell line), but that time could be extended once the drug reservoir can be reloaded without removing the catheter. In vivo short-term studies were also performed in porcine models, and the therapeutic MMC concentration was released after 2 h. However, optimization of the system and longer pre-clinical studies are needed, as little or no MMC tissue uptake was observed [ 23 ].…”

Section: Fundamentalsmentioning

confidence: 99%

Mucoadhesive Polymers and Their Applications in Drug Delivery Systems for the Treatment of Bladder Cancer

Varca

Alves

Nogueira

et al. 2022

Gels

View full text Add to dashboard Cite

Bladder cancer (BC) is the tenth most common type of cancer worldwide, affecting up to four times more men than women. Depending on the stage of the tumor, different therapy protocols are applied. Non-muscle-invasive cancer englobes around 70% of the cases and is usually treated using the transurethral resection of bladder tumor (TURBIT) followed by the instillation of chemotherapy or immunotherapy. However, due to bladder anatomy and physiology, current intravesical therapies present limitations concerning permeation and time of residence. Furthermore, they require several frequent catheter insertions with a reduced interval between doses, which is highly demotivating for the patient. This scenario has encouraged several pieces of research focusing on the development of drug delivery systems (DDS) to improve drug time residence, permeation capacity, and target release. In this review, the current situation of BC is described concerning the disease and available treatments, followed by a report on the main DDS developed in the past few years, focusing on those based on mucoadhesive polymers as a strategy. A brief review of methods to evaluate mucoadhesion properties is also presented; lastly, different polymers suitable for this application are discussed.

show abstract

A new catheter-integrated drug-delivery system for controlled intravesical mitomycin C release

Cited by 8 publications

References 20 publications

Development of an ex-vivo porcine lower urinary tract model to evaluate the performance of urinary catheters

Development of an ex-vivo porcine lower urinary tract model to evaluate the performance of urinary catheters

Clean-catching urine from pigs: A method for collecting quality specimens for urinalysis and microbiological culturing in a laboratory environment

Mucoadhesive Polymers and Their Applications in Drug Delivery Systems for the Treatment of Bladder Cancer

Contact Info

Product

Resources

About